choi dongsu/iStock via Getty Images
Clinical-stage biotech Viking Therapeutics (NASDAQ:VKTX) added ~39% pre-market Tuesday after announcing that its obesity candidate VK2735 led to an average body weight reduction of up to ~8% in a Phase 1 trial.
The randomized study involved healthy adults who received escalating single doses of VK2735 in one portion and once weekly doses for 28 days in the other portion called MAD, which enrolled those with a minimum body mass index of 30 Kg per meter squared.
Viking (VKTX) said that all cohorts in the MAD portion achieved mean body weight reductions ranging up to 7.8% from the baseline and up to 6.0% mean reductions relative to the placebo.
According to the company, statistically significant changes in therapeutic effects compared to placebo were maintained or improved at Day 43 follow-up or 21 days after the last VK2735 dose.
Regarding overall safety data, 98% of adverse events were mild to moderate, while one subject who received VK2735 developed a serious adverse event (SAE). A subject with a history of gallstones experienced an SAE of gallstone obstruction.
Viking (VKTX) plans to begin a Phase 2 obesity trial for VK2735 in mid-2023.
Read: Seeking Alpha contributor Terry Chrisomalis issued a Strong Buy on the company in December citing its prospects against liver disease non-alcoholic steatohepatitis (NASH).
"stage" - Google News
March 28, 2023 at 06:19PM
https://ift.tt/KpG8Wwz
Viking stock jumps on early-stage data for obesity drug (NASDAQ:VKTX) - Seeking Alpha
"stage" - Google News
https://ift.tt/xIFeMQv
https://ift.tt/PW0NrM7
Bagikan Berita Ini
0 Response to "Viking stock jumps on early-stage data for obesity drug (NASDAQ:VKTX) - Seeking Alpha"
Post a Comment